BUY LUMAKRAS (SOTORASIB) ONLINE

WHAT IS LUMAKRAS (SOTORASIB) FOR?
LUMAKRAS (SOTORASIB) IS A PRESCRIPTION MEDICINE USED TO TREAT ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC):[1]

THAT HAS SPREAD TO OTHER PARTS OF THE BODY OR CANNOT BE REMOVED BY SURGERY, AND
WHOSE TUMOR HAS AN ABNORMAL KRAS G12C GENE, AND
WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC TREATMENT FOR THEIR CANCER.
IT IS AVAILABLE IN TABLET FORM CONTAINING 120 MG SOTORASIB.[1]

HOW DOES LUMAKRAS (SOTORASIB) WORK?
13% OF PATIENTS WITH NSCLC HAVE AN ABNORMAL KRAS G12C GENE. KRAS IS AN ONCOGENE, A GENE THAT IS A MUTATED (CHANGED) FORM OF A GENE INVOLVED IN NORMAL CELL GROWTH. IT PRODUCES THE MUTANT FORM OF THE KRAS PROTEIN, WHICH DRIVES THE DEVELOPMENT OF LUNG AND OTHER CANCER.[2,3]

LUMAKRAS CONTAINS THE ACTIVE INGREDIENT SOTORASIB, WHICH IS DESIGNED TO INACTIVATE THE MUTATED PROTEIN. THEREBY IT CAN BLOCK TUMOR GROWTH AND SLOW DOWN THE DISEASE.[2,3]

IT IS NOT A CHEMOTHERAPY, IMMUNOTHERAPY, OR TYROSINE KINASE INHIBITOR. IT’S AN ORAL INHIBITOR DESIGNED SPECIFICALLY FOR PATIENTS WITH A KRAS G12C MUTATION.[2,3]

WHERE HAS LUMAKRAS (SOTORASIB) BEEN APPROVED?
LUMAKRAS (SOTORASIB) WAS APPROVED FOR THE TREATMENT OF PEOPLE WITH KRAS G12C-MUTATED ADVANCED NSCLC BY:

THE FOOD AND DRUG ADMINISTRATION (FDA), USA ON MAY 28, 2021.[4]
LUMAKRAS (SOTORASIB) WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE U.S. AND CHINA.[4]

IT IS ALSO BEING STUDIED IN MULTIPLE OTHER SOLID TUMORS.[4]

PLEASE NOTE THAT THIS MEDICINE MAY HAVE ALSO BEEN APPROVED IN OTHER REGIONS THAN THE ONES WE’VE LISTED. IF YOU HAVE A QUESTION ABOUT ITS APPROVAL IN A SPECIFIC COUNTRY FEEL FREE TO CONTACT OUR SUPPORT TEAM.

HOW IS LUMAKRAS (SOTORASIB) TAKEN?
THE STANDARD DOSAGE IS:[1]

960 MG (EIGHT 120 MG TABLETS) TAKEN ORALLY ONCE DAILY
TAKE THE TABLETS AT THE SAME TIME EACH DAY WITH OR WITHOUT FOOD. TAKE THIS MEDICINE UNTIL THE DISEASE PROGRESSES OR UNACCEPTABLE SIDE EFFECTS OCCUR.[1]

IF VOMITING OCCURS AFTER TAKING THE TABLETS, DO NOT TAKE AN ADDITIONAL DOSE. TAKE THE NEXT DOSE AS PRESCRIBED THE NEXT DAY.[1]

IF ADVERSE REACTIONS OCCUR, THE DOSE SHOULD BE REDUCED.[1]

AVOID TAKING THIS MEDICINE WITH ACID-REDUCING AGENTS, INCLUDING PROTON PUMP INHIBITOR (PPI) MEDICINES OR H2 BLOCKERS. IF YOU TAKE AN ANTACID MEDICINE, TAKE LUMAKRAS EITHER 4 HOURS BEFORE OR 10 HOURS AFTER THE ANTACID.[1]

COMPLETE INFORMATION ABOUT LUMAKRAS (SOTORASIB) DOSAGE (MODIFICATIONS) AND ADMINISTRATION CAN BE FOUND IN THE OFFICIAL PRESCRIBING INFORMATION LISTED IN OUR REFERENCES SECTION.[1]

NOTE: PLEASE CONSULT WITH YOUR TREATING DOCTOR FOR PERSONALISED DOSING.

ARE THERE ANY KNOWN ADVERSE REACTIONS OR SIDE EFFECTS OF LUMAKRAS (SOTORASIB)?
COMMON ADVERSE REACTIONS
THE MOST COMMON SIDE EFFECTS ( ≥5% OF PATIENTS) LISTED IN THE PRESCRIBING INFORMATION INCLUDE:[1]

DIARRHEA
MUSCLE OR BONE PAIN
NAUSEA
TIREDNESS
LIVER PROBLEMS
COUGH
CHANGES IN LIVER FUNCTION TESTS
CHANGES IN CERTAIN OTHER BLOOD TESTS
SERIOUS ADVERSE REACTIONS
THE SERIOUS ADVERSE REACTIONS LISTED IN THE PRESCRIBING INFORMATION INCLUDE:[1]

LIVER PROBLEMS
LUNG OR BREATHING PROBLEMS
USE IN A SPECIFIC POPULATION
IT IS NOT KNOWN IF LUMAKRAS WILL HARM YOUR UNBORN BABY. IT IS NOT KNOWN IF LUMAKRAS PASSES INTO YOUR BREAST MILK. DO NOT BREASTFEED DURING TREATMENT, AND FOR 1 WEEK AFTER THE FINAL DOSE.[1]

FOR A COMPREHENSIVE LIST OF SIDE EFFECTS AND ADVERSE REACTIONS PLEASE REFER TO THE OFFICIAL PRESCRIBING INFORMATION.[1]